Abstract Details

Title Infliximab Treatment in Neuro-Behcet Disease Unresponsive to Immunosuppressive Treatments: Clinical Assessment of Eleven Patients

Topic Neurotoxicology

Presentation(s) P01 - (-)

Poster/Presentation
Number 055

Objective

Background Tumor necrosis factor-? (TNF?) plays crucial role in the pathogenesis of active Behcet Disease (BD) and a monoclonal antibody neutralizing TNF-? named infliximab is an alternative treatment option in patients resistant to conventional immunosuppressive therapies. But still there is no large studies on infliximab treatment in neuro-Behcet Disease (NBD). Here we report 11 patients treated with infliximab in our inpatient clinic.

Design/Methods Nine patients with parenchymal, one patient with non-parenchymal NBD and one patient with both parenchymal and non-parenchymal involvement were recruited. Nine of the patients were men and two patients were women. Patients mean age was 38.7±5.5. BD and NBD disease duration at the time of infliximab administration were 5.5±5.3 and 2.8±3.6 years respectively and all patients were treated with immunosuppressive treatment before infliximab. Infliximab treatment duration was 29.5±22.8 months.

Results Four patients showed clinically significant improvement and seven patients were in remission. None of patients showed adverse effects due to infliximab treatment. The average EDSS scores before and after infliximab treatment were 4.41 and 3.95 respectively.

Conclusions Infliximab, a monoclonal antibody neutralizing TNF-? is used especially in uveitis, gastrointestinal involvement of BD and NBD. Our study shows that infliximab alone or combined with immunosuppressive therapies prevents disease progression or provides clinical improvement in NBD patients who are resistant to immunosuppressive treatment.

Authors/Disclosures
PRESENTER	No disclosure on file
Ugur Uygunoglu (Cerrahpasa)	Ugur Uygunoglu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Turkey . The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec/Gen Pharma of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck-Serono of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanovel of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genveon of Turkey.
	No disclosure on file
	No disclosure on file
Sanjay Pandey, MD (Department of Neurology and Stroke Medicine)	Dr. Pandey has nothing to disclose.
	No disclosure on file
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine)	Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.

��ɫ��

��ɫ��